Table 1

Demographic and clinical characteristics of study participants, stratified by immune response to the first dose of SARS-CoV-2 mRNA vaccine

Overall
(n=123)
Detectable antibody (n=91)Undetectable antibody (n=32)P value*
Age, median (IQR)50 (41, 61)46 (37, 61)57 (43, 68)0.06
Female sex, n (%)117 (95)87 (96)30 (94)0.7
Non-white, n (%)12 (10)11 (12)1 (3)0.2
Diagnosis, n (%)
 Inflammatory arthritis†34 (28)29 (32)5 (16)0.5
 Systemic lupus erythematous24 (20)16 (18)8 (25)
 Sjogren’s syndrome16 (13)12 (13)4 (12)
 Myositis7 (6)4 (4)3 (9)
 Vasculitis2 (2)1 (1)1 (3)
 Overlap connective tissue disease‡35 (29)25 (27)10 (31)
 Other5 (4)4 (4)1 (3)
Therapy, n (%)
 None34 (28)28 (31)6 (19)0.5
 Non-biologic DMARD§23 (19)16 (18)7 (22)
 Biologic DMARD¶17 (14)11 (12)6 (19)
 Corticosteroid monotherapy**4 (3)4 (4)0 (0)
 Combination therapy45 (37)32 (35)13 (41)
  • *Comparing the detectable antibody group with the undetectable antibody group.

  • †Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis and inflammatory bowel disease-associated arthritis.

  • ‡Overlap connective tissue disease denotes a combination of two or more of the above conditions, also includes systemic sclerosis.

  • §Azathioprine, hydroxychloroquine, leflunomide, methotrexate, mycophenolate, sulfasalazine and tacrolimus.

  • ¶Adalimumab, certolizumab, etanercept, infliximab, tocilizumab, ustekinumab, ixekizumab, belimumab, rituximab, tofacitinib and abatacept.

  • **Prednisone and prednisone equivalents.

  • DMARD, disease-modifying antirheumatic drug; mRNA, messenger RNA.